Heart Failure with Preserved Ejection Fraction (HFpEF), a prospective cohort

Heart Failure with Preserved Ejection Fraction (HFpEF), a prospective cohort - HFpEF cohort

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50023

Enrollment

1000

Registered

2019-04-17

Start date

2019-04-23

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hartaandoeningen, falen van de hartfunctie Heart failure with preserved ejection fraction

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients referred with exertional dyspnea to the HFpEF clinic from the general HF, general cardiology outpatient clinic or directly from their general practitioners above 18 years that have the ability to give the informed consent and sign it will be included in the cohort and blood and urine samples for the biobank will be obtained. , 20 hypertensive control patients will be included. These are their inclusion criteria: o Age > 50 years o Estimated glomerular filtration reserve (eGFR) >30 ml/min o Body weight70% or history of CABG) o No heart failure o Preserved left ventricular ejection fraction (LVEF) (>= 50%) on echocardiography o No left ventricular hypertrophy (lateral and septal left ventricular wall =140/90 mmHg or use of anti-hypertensive therapy o Normal cardiac structure and function on echocardiography

Exclusion criteria

Exclusion criteria: - Inability to give informed consent or refusal to participate in the study - Age

Design outcomes

Primary

Measure	Time frame
(1) Set up a cohort of HFpEF patients with an detailed clinical characterization of their phenotype.	—

Secondary

Measure	Time frame
2. Set up a cohort of HFpEF patients with detailed clinical characterization of their phenotype. 3. Set up a biobank, to analyse different biomarker profiles which will help to stratify HFpEF patients 4. Investigate if patients without HFpEF, hypertensive controls that will be included in the HFpEF-cohort perfusion and metabolism study( NL57468.068.16/ METC162032) have different biomarker profiles compared to the HFpEF patients. 5. Isolate monocytes, neutrophils, T cells and platelets in HFpEF and hypertensive control patients included in the HFpEF-cohort perfusion and metabolism study (NL57468.068.16/METC162032) to understand better the pathophysiology, phenotype HFpEF patients and assess the differences with patients without HFpEF. 6. Evaluate the changes in biomarker, urine and cellular expression (monocytes, neutrophils, T cells and platelets) after one year of all HFpEF patients included in the cohort and clinically followed up in out out-patient clinic. Evaluate whether our personalized, multidisciplinary treatment strategy improves quality of life and exercise tolerability, and reduces hospitalizations 7. Increase awareness around this challenging syndrome. 8. Evaluate platelet function by analysing extracellular vesicles in blood of hypertensive control patients that in future projects will be compared to HFpEF patients.	—

Measure

Time frame

2. Set up a cohort of HFpEF patients with detailed clinical characterization of their phenotype. 3. Set up a biobank, to analyse different biomarker profiles which will help to stratify HFpEF patients 4. Investigate if patients without HFpEF, hypertensive controls that will be included in the *HFpEF-cohort perfusion and metabolism study*( NL57468.068.16/ METC162032) have different biomarker profiles compared to the HFpEF patients. 5. Isolate monocytes, neutrophils, T cells and platelets in HFpEF and hypertensive control patients included in the *HFpEF-cohort perfusion and metabolism study* (NL57468.068.16/METC162032) to understand better the pathophysiology, phenotype HFpEF patients and assess the differences with patients without HFpEF. 6. Evaluate the changes in biomarker, urine and cellular expression (monocytes, neutrophils, T cells and platelets) after one year of all HFpEF patients included in the cohort and clinically followed up in out out-patient clinic. Evaluate whether our personalized, multidisciplinary treatment strategy improves quality of life and exercise tolerability, and reduces hospitalizations 7. Increase awareness around this challenging syndrome. 8. Evaluate platelet function by analysing extracellular vesicles in blood of hypertensive control patients that in future projects will be compared to HFpEF patients.

—

Countries

Netherlands

Outcome results